As a science-driven company, we continuously publish scientific publications in high-impact journals, and contribute with congress-abstracts with preliminary data. Please feel free to contact our Science-team if you have questions or comments to our publications, or proposals for new scientific collaborations: science@blueskincro.com
Osteoarthritis (OA) development programmes face challenges due to discordance between structural changes and symptoms. A novel cathepsin-K inhibitor, MIV-711, recently reported structural benefits, but did not demonstrate a significant difference from placebo in symptoms. Previous work suggests that pain from non-target joints may confound OA pain outcomes. We therefore conducted an exploratory analysis in participants with predominantly unilateral knee pain from the MIV-711-201 trial.
Home Clinical and Experimental Rheumatology
© 2025 blueskincro.com